Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

NCT05432791 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05432791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05432791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 30, 2023
Completion date
January 30, 2027
Enrollment
74 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced uterine corpus leiomyosarcoma, metastatic uterine corpus leiomyosarcoma, stage iii uterine corpus leiomyosarcoma ajcc v8, stage iv uterine corpus leiomyosarcoma ajcc v8, unresectable uterine corpus leiomyosarcoma